Skip to content
  • Latest News
  • Advertising Policy
  • Contact Us
  • Cookie Policy
  • Privacy Policy
  • Terms and Conditions
  • About Us
Archyde

Archyde

  • News
  • World
  • Economy
  • Technology
  • Health
  • Entertainment
  • Sport

MASLD

Liver damage such as Fatty liver, Fibrosis, Cirrhosis, and Liver cancer

GLP-1 Agonists Show Biopsy-Confirmed MASH Resolution; FDA Grants Accelerated Approval

November 20, 2026 by Health Desk

GLP-1 receptor agonists, the drug class behind semaglutide, are now showing biopsy-confirmed benefits in MASH, the inflammatory form of fatty liver disease, with a 72-week trial reporting resolution in 62.9% … Read More

Categories Health Tags Clinical trials, Fatty liver, liver fibrosis, MASH, MASLD, Metabolic Health, semaglutide

Recent Posts

  • Austrian Chancellor Condemns Russian Strike on Kyiv Embassy
  • Three-Sport Athlete Endured 14-Year Delay Before Stage IV Endometriosis Excision Surgery
  • Epic Games Store Gives Away Mark of the Deep; Alien: Isolation No-Show
  • Hortmannlaw: Love-Scam Victims Can File DSA Article 16 Notices to Document Meta’s Knowledge
  • Elly Schlein Endorses GTA VI on Instagram
  • Latest News
  • Advertising Policy
  • Contact Us
  • Cookie Policy
  • Privacy Policy
  • Terms and Conditions
  • About Us
© 2026 Archyde — All Rights Reserved. Contact | Privacy Policy